Post-diagnostic beta blocker use and breast cancer-specific mortality: a population-based cohort study

Abstract

Purpose Beta blockers (BB) have been associated with improved, worsened, or unchanged breast cancer outcomes in previous studies. This study examines the association between the post-diagnostic use of BBs and death from breast cancer in a large, representative sample of New Zealand (NZ) women with breast cancer. Methods Women diagnosed with a first primary breast cancer between 2007 and 2016 were identified from four population-based regional NZ breast cancer registries and linked to national pharmaceutical data, hospital discharges, and death records. The median follow-up time was 4.51 years. Cox proportional hazard models were used to estimate the hazard of breast cancer-specific death (BCD) associated with any post-diagnostic BB use. Results Of the 14,976 women included in analyses, 21% used a BB after diagnosis. BB use (vs non-use) was associated with a small and nonstatistically significant increased risk of BCD (adjusted hazard ratio: 1.11; 95% CI 0.95–1.29). A statistically significant increased risk confined to short-term use (0–3 months) was seen (HR = 1.40; 1.14–1.73), and this risk steadily decreased with increasing duration of use and became a statistically significant protective effect at 3 + years of use (HR = 0.55; 0.34–0.88). Conclusion Our findings suggest that any increased risk associated with BB use may be driven by risk in the initial few months of use. Long-term BB use may be associated with a reduction in BCD.

Post-diagnostic statin use and breast cancer-specific mortality: a population-based cohort study

“…2–6 weeks) [ 43 , 44 ]. As evidenced by Supplementary Table 3, those who took statins in the lowest dose categories generally had a shorter median time to death/last follow up than those with took statins in the higher dose categories (a similar phenomenon was evidenced in a previous paper of ours for beta blockers [ 81 ]). Therefore, the slightly higher HRs observed in the 0–3 month and 3–6 month dose categories may in fact be an artefact of women in these dose categories being dispensed statins towards the end of their life.…”

Breast cancer and neurotransmitters: emerging insights on mechanisms and therapeutic directions

“…Furthermore, a meta-analysis of studies published between 2010 and 2013 found that women with breast cancer who took beta blockers had a significantly decreased risk of breast cancer death than women with breast cancer who did not take beta blockers [ 20 ]. A recent meta-analysis of nearly 15,000 New Zealand breast cancer patients saw a short term—over 3 months—increased risk of death among patients who took beta blockers post-diagnosis, and a protective effect with long-term use [ 32 ].…”

An endothelial SOX18-mevalonate pathway axis enables repurposing of statins for infantile hemangioma

“…Propranolol is currently being studied as single administration adjuvant therapy or in combination with standard therapies in several clinical trials (57). Statin use was first found associated with improved outcomes in colorectal cancer patients in 2005 (58) and subsequent studies confirmed this observation and extend to postdiagnosis statin use (59)(60)(61)(62)(63)(64).…”